Sangamo Therapeutics Inc

SGMO

0.400USD

+0.047+13.15%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Sangamo Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

161 / 392

Overall Ranking

309 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Sangamo Therapeutics Inc Highlights

StrengthsRisks

Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.

Growing

The company is in a growing phase, with the latest annual income totaling USD 57.80M.

Fairly Valued

The company’s latest PE is -0.91, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 63.00M shares, decreasing 43.76% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 808.73K shares of this stock.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

3.813

Target Price

+978.50%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Sangamo Therapeutics Inc is 5.55, ranking 350 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 581.00K, representing a year-over-year decrease of 98.82%, while its net profit experienced a year-over-year decrease of 472.19%.

Score

Industry at a Glance

Previous score

5.55

Change

0



Financials

5.50

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.42

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.92

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Sangamo Therapeutics Inc is 7.41, ranking 124 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.91, which is -79.06% below the recent high of -0.19 and -341.03% above the recent low of -4.02.

Score

Industry at a Glance

Previous score

7.41

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 161/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Sangamo Therapeutics Inc is 7.60, ranking 276 out of 392 in the Biotechnology & Medical Research industry. The average price target is 2.00, with a high of 10.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.60

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Sangamo Therapeutics Inc is 6.33, ranking 265 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.55 and the support level at 0.30, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.03

Change

0.3

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Sangamo Therapeutics Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 18.72%, representing a quarter-over-quarter increase of 13.68%. The largest institutional shareholder is The Vanguard, holding a total of 12.00M shares, representing 3.36% of shares outstanding, with 19.24% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

11.62M

+23.90%

Renaissance Technologies LLC

Star Investors

10.18M

+48.88%

Two Sigma Investments, LP

4.65M

+123.29%

BlackRock Institutional Trust Company, N.A.

4.55M

+8.98%

Geode Capital Management, L.L.C.

3.29M

+40.91%

Biogen Inc

3.25M

-77.82%

Susquehanna International Group, LLP

2.42M

+213.01%

Jane Street Capital, L.L.C.

2.20M

--

Macrae (Sandy)

2.05M

-0.36%

Charles Schwab Investment Management, Inc.

1.54M

+20.07%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Sangamo Therapeutics Inc is 2.42, ranking 229 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.36. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Sangamo Therapeutics Inc

SGMO

5.83 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment